Beta-Defensin vs TA1
A side-by-side research comparison of Beta-Defensin and TA1 across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Beta-Defensin | TA1 |
|---|---|---|
| Full name | Human Beta-Defensin Peptides | Thymosin Alpha-1 (TA1 - Clinical Form) |
| Category | Immune Support | Immune Support |
| Status | Research compound | Approved internationally (not FDA-approved) |
| Mechanism | Form pores in microbial membranes causing lysis, recruit immune cells via CCR6 receptor chemotaxis, and bridge innate and adaptive immunity by activating dendritic cells. | Activates TLR2/9 on dendritic cells, promotes T-cell differentiation, and enhances cytokine-mediated immune signaling cascades. |
| Molecular weight | 4000-5000 Da | 3108.3 Da |
| Half-life | ~2-4 hours | ~2-3 hours |
| Bioavailability | Primarily local/mucosal activity | ~85% subcutaneous |
| Typical dose | 50-200 mcg | 1.6 mg |
| Frequency | Daily or as needed | 2x per week |
| Route | Topical or subcutaneous | Subcutaneous injection |
Beta-Defensin reported benefits
- Broad antimicrobial activity
- Immune cell recruitment
- Wound healing support
- Biofilm disruption
TA1 reported benefits
- Standardized immune enhancement
- Proven antiviral adjunct
- Cancer immunotherapy support
- Vaccine response enhancement
Related comparisons
Research and educational reference only. Not medical advice.